A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9.

The CDC's vaccine advisory committee voted on Thursday to recommend infants receive a newer monoclonal antibody shot for respiratory syncytial virus.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.